Trials / Completed
CompletedNCT02277743
Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 671 (actual)
- Sponsor
- Regeneron Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a randomized, double-blind, placebo-controlled, parallel group study to confirm the efficacy and safety of Dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis (AD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dupilumab | Subcutaneous injection alternated among the different quadrants of the abdomen, upper thighs and upper arms |
| DRUG | Placebo (for Dupilumab) | Subcutaneous injection alternated among the different quadrants of the abdomen, upper thighs and upper arms |
Timeline
- Start date
- 2014-10-01
- Primary completion
- 2015-11-01
- Completion
- 2016-02-01
- First posted
- 2014-10-29
- Last updated
- 2017-11-21
- Results posted
- 2017-11-21
Locations
101 sites across 10 countries: United States, Bulgaria, Canada, Denmark, Estonia, Finland, Germany, Japan, Singapore, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02277743. Inclusion in this directory is not an endorsement.